Back to Search
Start Over
Rituximab for treatment of inhibitors in haemophilia A
- Source :
- Thrombosis and Haemostasis. 112:445-458
- Publication Year :
- 2014
- Publisher :
- Georg Thieme Verlag KG, 2014.
-
Abstract
- SummaryThe development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m2 weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8%) met the criteria for a major response, defined as a fall in inhibitor titre to Trial: “Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A: The RICH Study. Registered as Clinical Trials.gov identifier- NCT00331006.
- Subjects :
- Adult
Male
0301 basic medicine
congenital, hereditary, and neonatal diseases and abnormalities
medicine.medical_specialty
Adolescent
Haemophilia A
Phases of clinical research
030204 cardiovascular system & hematology
Hemophilia A
Bethesda unit
Gastroenterology
Article
Immune tolerance
Antibodies, Monoclonal, Murine-Derived
Young Adult
03 medical and health sciences
0302 clinical medicine
hemic and lymphatic diseases
Internal medicine
medicine
Humans
Antibodies, Blocking
Child
Blood Coagulation
Factor VIII
biology
business.industry
Hematology
Antigens, CD20
medicine.disease
United States
Treatment Outcome
030104 developmental biology
Child, Preschool
Antibody Formation
Monoclonal
Immunology
biology.protein
Rituximab
Antibody
business
Complication
Immunosuppressive Agents
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 2567689X and 03406245
- Volume :
- 112
- Database :
- OpenAIRE
- Journal :
- Thrombosis and Haemostasis
- Accession number :
- edsair.doi.dedup.....51746c62c4078bf482ec1ab849e0fd69